[1]
|
Goff Jr., D.C., Lloyd-Jones, D.M., Bannett, G., et al. (2014) 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 63, 2935-2959. https://doi.org/10.1016/j.jacc.2013.11.005
|
[2]
|
Malakar, A.K., Choudhury, D., Halder, B., Paul, P., Uddin, A. and Chakraborty, S. (2019) A Review on Coronary Artery Disease, Its Risk Factors, and Therapeutics. Journal of Cellular Physiology, 234, 16812-16823.
https://doi.org/10.1002/jcp.28350
|
[3]
|
安宁, 邹德玲. 小而密低密度脂蛋白胆固醇及其与高密度脂蛋白胆固醇比值与急性冠状动脉综合征的相关性研究[J]. 中国医师进修杂志, 2018, 41(12): 1080-1085.
|
[4]
|
Xiao, C., Dash, S., Morgantini, C., Hegele, R.A. and Lewis, G.F. (2016) Pharmacological Targeting of Theatherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention beyond Lowering LDL C Cholesterol. Diabetes, 65, 1767-1778. https://doi.org/10.2337/db16-0046
|
[5]
|
Catapano, A.L., Graham, I., De Backer, G., Wiklund, O., John Chapman, M., Drexel, H., et al. (2016) ESC/EAS Guidelines for the Management of Dyslipidaemias: The T Ask Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Atherosclerosis, 253, 281-344.
https://doi.org/10.1016/j.atherosclerosis.2016.08.018
|
[6]
|
Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel Members (2014) An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia—Full Report. Journal of Clinical Lipidology, 8, 29-60. https://doi.org/10.1016/j.jacl.2013.12.005
|
[7]
|
Rosenson, R.S., Bryan Brewer Jr., H., Ansell, B.J., Barter, P., John Chapman, M., Heinecke, J.W., et al. (2016) Dysfunctional HDL and Atherosclerotic Cardiovascular Disease. Nature Reviews Cardiology, 13, 48-60.
https://doi.org/10.1038/nrcardio.2015.124
|
[8]
|
Langsted, A., Madsen, C.M. and Nordestgaard, B.G. (2020) Contribution of Remnant Cholesterol to Cardiovascular Risk. Journal of Internal Medicine, 288, 116-127. https://doi.org/10.1111/joim.13059
|
[9]
|
Diffenderfer, M.R. and Schaefer, E.J. (2014) The Compositionand Metabolism of Large and Small LDL. Current Opinion in Lipidology, 25, 221-226. https://doi.org/10.1097/MOL.0000000000000067
|
[10]
|
Balling, M., Nordestgaard, B.G., Langsted, A., Varbo, A., Kamstrup, P.R. and Afzal, S. (2020) Small Dense Low-Density Lipoprotein Cholesterol Predicts Atherosclerotic Cardiovascular Disease in the Copenhagen General Population Study. Journal of the American College of Cardiology, 75, 2873-2875.
https://doi.org/10.1016/j.jacc.2020.03.072
|
[11]
|
Ivanova, E.A., Myasoedova, V.A., Melnichenko, A.A., Grechko, A.V. and Orekhov, A.N. (2017) Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases. Oxidative Medicine and Cellular Longevity, 2017, Article ID: 1273042. https://doi.org/10.1155/2017/1273042
|
[12]
|
Chen, G.C., Liu, W., Duchateau, P., Allaart, J., Hamilton, R.L., Mendel, C.M., et al. (1994) Conformational Differences in Human Apolipoprotein B-100 among Subspecies of Low Density Lipoproteins (LDL). Association of Alteredproteolytic Accessibility with Decreased Receptor Binding of LDL Subspecies from Hypertriglyceridemic Subjects. Journal of Biological Chemistry, 269, 29121-29128. https://doi.org/10.1016/S0021-9258(19)62020-X
|
[13]
|
Packard, C.J., Demant, T., Stewart, J.P., Bedford, D., Caslake, M.J., Schwertfeger, G., et al. (2000) Apolipoprotein B Metabolism and the Distribution of VLDL and LDL Subfractions. Journal of Lipid Research, 41, 305-317.
https://doi.org/10.1016/S0022-2275(20)32065-4
|
[14]
|
Wang, H., Wang, H.M., Jin, Q.H., Cong, H., Zhuang, G.S., Zhao, J.L., et al. (2008) Microchip-Based Small, Dense Low-Density Lipoproteins Assay for Coronary Heart Disease Risk Assessment. Electrophoresis, 29, 1932-1941.
https://doi.org/10.1002/elps.200700631
|
[15]
|
Wu, J., Shi, Y.H., Niu, D.M., Li, H.Q., Zhang, C.N. and Wang, J.J. (2012) Association among Retinol-Binding Protein 4, Small Dense LDL Cholesterol and Oxidized LDL Levels in Dyslipidemia Subjects. Clinical Biochemistry, 45, 619-622. https://doi.org/10.1016/j.clinbiochem.2012.02.022
|
[16]
|
Hoogeveen, R.C., Gaubatz, J.W., Sun, W., Dodge, R.C., Crosby, J.R., Jiang, J., et al. (2014) Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 34, 1069-1077. https://doi.org/10.1161/ATVBAHA.114.303284
|
[17]
|
Li, G., Wu, H.K., Wu, X.W., Cao, Z., Tu, Y.-C., Ma, Y., et al. (2018) Small Dense Low Density Lipoprotein-Cholesterol and Cholesterol Ratios to Predict Arterial Stiffness Progression in Normotensive Subjects over a 5-Yearperiod. Lipids in Health and Disease, 17, Article No. 27. https://doi.org/10.1186/s12944-018-0671-2
|
[18]
|
Laurent, S., Cockcroft, J., Van Bortel, L., Boutouyrie, P., Giannattasio, C., Hayoz, D., et al. (2006) Expert Consensus Document on Arterial Stiffness: Methodological Issues and Clinical Applications. European Heart Journal, 27, 2588-2605.
https://doi.org/10.1093/eurheartj/ehl254
|
[19]
|
Fukushima, Y., Hirayama, S., Ueno, T., Dohi, T., Miyazaki, T., Ohmura, H., et al. (2011) Small Dense LDL Cholesterol Is a Robust Therapeutic Marker of Statin Treatment in Patients with Acute Coronary Syndrome and Metabolic Syndrome. Clinica Chimica Acta, 412, 1423-1427. https://doi.org/10.1016/j.cca.2011.04.021
|
[20]
|
Nordestgaard, B.G. and Varbo, A. (2014) Triglycerides and Cardiovascular Disease. Lancet, 384, 626-635.
https://doi.org/10.1016/S0140-6736(14)61177-6
|
[21]
|
Ferrari, R., Aguiar, C., Alegria, E., Bonadonna, R.C., Cosentino, F, Elisaf, M., et al. (2016) Current Practice in Identifying and Treating Cardiovascular Risk, with Focus on Residual Risk Associated with Atherogenic Dyslipidaemia. European Heart Journal Supplements, 18, C2-C12. https://doi.org/10.1093/eurheartj/suw009
|
[22]
|
Puri, R., Nissen, S.E., Shao, M., Elshazly, M.B., Kataoka, Y., Kapadia, S.R., Murat Tuzcu, E., et al. (2016) Non-HDL Cholesterol and Triglycerides. Implications for Coronary Atheroma Progression and Clinical Events. Arteriosclerosis, Thrombosis, and Vascular Biology, 36, 2220-2228. https://doi.org/10.1161/ATVBAHA.116.307601
|
[23]
|
Zheng, C., Khoo, C., Furtado, J. and Sacks, F.M. (2010) Apolipoprotein C-III and the Metabolic Basis for Hypertriglyceridemia and the Dense Low-Density Lipoprotein Phenotype. Circulation, 121, 1722-1734.
https://doi.org/10.1161/CIRCULATIONAHA.109.875807
|
[24]
|
Adiels, M., Olofsson, S.-O., Taskinen, M.-R. and Borén, J. (2008) Overproduction of Very Low Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 1225-1236. https://doi.org/10.1161/ATVBAHA.107.160192
|
[25]
|
Reiner, Ž. (2017) Hypertriglyceridaemia and Risk of Coronary Artery Disease. Nature Reviews Cardiology, 14, 401-411. https://doi.org/10.1038/nrcardio.2017.31
|
[26]
|
Alizadeh-Fanalou, S., Nazarizadeh, A., Alian, F., Faraji, P., Sorori, B. and Khosravi, M. (2020) Small Dense Low-Density Lipoprotein-Lowering Agents. Biological Chemistry, 401, 1101-1121. https://doi.org/10.1515/hsz-2019-0426
|
[27]
|
Bahadir, M.A., Oguz, A., Uzunlulu, M. and Bahadir, O. (2009) Effectsof Different Statin Treatments on Small Dense Low-Densitylipoprotein in Patients with Metabolic Syndrome. Journal of Atherosclerosis and Thrombosis, 16, 684-690.
https://doi.org/10.5551/jat.1123
|
[28]
|
Florentin, M., Liberopoulos, E.N., Moutzouri, E., Rizos, C.V., Tselepis, A.D. and Elisaf, M.S. (2011) The Effect of Simvastatin Aloneversus Simvastatin Plus Ezetimibe on the Concentration of Smalldense Low-Density Lipoprotein Cholesterol in Subjects with Primary Hypercholesterolemia. Current Medical Research and Opinion, 27, 685-692.
https://doi.org/10.1185/03007995.2010.546394
|
[29]
|
Scheen, A.J. (2015) Pharmacodynamics, Efficacy and Safety of Sodium-Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus. Drugs, 75, 33-59. https://doi.org/10.1007/s40265-014-0337-y
|
[30]
|
Galletti, F., Fazio, V., Gentile, M., Schillaci, G., Pucci, G., Battista, F., Mercurio, V., Bosso, G., Bonaduce, D., Brambilla, N., et al. (2019) Efficacy of a Nutraceutical Combination on Lipid Metabolism in Patients with Metabolic Syndrome: A Multicenter, Double Blind, Randomized, Placebo Controlled Trial. Lipids in Health and Disease, 18, Article No. 66. https://doi.org/10.1186/s12944-019-1002-y
|
[31]
|
Mason, R.P., Jacob, R., Corbalan, J.J. and Malinski, T. (2015) Eicosapentaenoic Acid Reduces Small Dense Low Densitylipoprotein Oxidation and Improves Endothelial Function in Vitro as Compared to Other Triglyceride-Lowering Agents. Journal of the American College of Cardiology, 65, A2139. https://doi.org/10.1016/S0735-1097(15)62139-8
|
[32]
|
Tuccinardi, D., Farr, O.M., Upadhyay, J., Oussaada, S.M., Klapa, M.I., Candela, M., Rampelli, S., Lehoux, S., Lazaro, I., Sala-Vila, A., et al. (2019) Mechanisms Underlying the Cardiometabolicprotective Effect of Walnut Consumption in Obese People: A Cross-Over, Randomized, Double-Blind, Controlled Inpatient Physiologystudy. Diabetes, Obesity and Metabolism, 21, 2086-2095. https://doi.org/10.1111/dom.13773
|
[33]
|
Lo, J.C., Wang, Y., Tumanov, A.V., Bamji, M., Yao, Z., Reardon, C.A., Getz, G.S. and Fu, Y.X. (2007) Lymphotoxin β Receptor-Dependent Control of Lipid Homeostasis. Science, 316, 285-288. https://doi.org/10.1126/science.1137221
|
[34]
|
Kwon, Y.J., Lee, H.S. and Lee, J.W. (2018) Direct Bilirubin Is Associated with Low-Density Lipoprotein Subfractions and Particle Size in Overweight and Centrally Obese Women. Nutrition, Metabolism & Cardiovascular Diseases, 28, 1021-1028. https://doi.org/10.1016/j.numecd.2018.05.013
|